Treatment of Sjogren's syndrome by administration of TR18 polypeptides
US7371388B1 · kind B1 · utility
7Cited by
0References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 26, 2004 |
| Grant date | May 13, 2008 |
| Priority date | — |
| Expiry date | Mar 6, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to TR18 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human TR18 protein. TR18 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR18 activity. The invention further relates to methods of treating, preventing, prognosing, or diagnosing an autoimmune disease or condition associated with an autoimmune disease, comprising administering to a patient an effective amount of polypeptides of the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.